drugset / Trial / NCT00402142

Dendritic Cell Vaccine in HIV-1 Infection

NCT00402142

Phase 1/2 Completed 60 enrolled Hospital Clinic of Barcelona
RandomizedParallel-groupQuadruple-blindTreatment

Summary

1. To study the efficacy of a therapeutic HIV vaccine consisting of autologous myeloid dendritic cells pulsed ex vivo with high doses of inactivated autologous HIV-1, in HIV-1 infected patients in a very early stages of the disease (CD4 \> 450 x 10 6 /L). 2. To analyze the HIV-1 humoral and cellular immune responses induced by this immune-based therapy.

Timeline

Start
2006-11
Primary completion
2011-12
Completion
2011-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator DC vaccine Vaccine Subcutaneous